投资者以证券欺诈罪起诉火箭制药公司和RxSight公司,并援引关于产品安全和需求的误导信息。 Investors sue Rocket Pharmaceuticals and RxSight for securities fraud, citing misleading information on product safety and demand.

火箭制药公司和RxSight的投资者面临集体诉讼,指控证券欺诈。 Investors in Rocket Pharmaceuticals and RxSight are facing class-action lawsuits alleging securities fraud. " 火箭制药公司 " 被指控误导股东了解其RP-A501临床试验的安全性,导致在林业发展局临床搁置后股票价格下降37%。 Rocket Pharmaceuticals is accused of misleading shareholders about the safety of its RP-A501 clinical trial, leading to a 37% stock price drop after an FDA clinical hold. RxSight被指控高报产品需求, 并面临「领养挑战」, 导致股价下跌38%。 RxSight is accused of overstating product demand and facing "adoption challenges," leading to a 38% drop in stock price. 遭受损失的投资者可以在不产生费用的情况下参加诉讼,提交索赔的最后期限即将临近。 Investors who suffered losses can join lawsuits without incurring costs, with deadlines approaching for filing claims.